Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9767808 | 0.81 | L3MBTL1 (0.75) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2894729 | 0.80 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12095206 | 0.79 | L3MBTL1 (0.72) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1120954 | 0.78 | L3MBTL1 (0.76) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL27470168 | 0.78 | L3MBTL1 (0.76) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2900809 | 0.77 | L3MBTL1 (0.50) | L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2902967 | 0.77 | HTT (0.53) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL21316935 | 0.75 | L3MBTL1 (0.71) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL28411595 | 0.74 | L3MBTL1 (0.69) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2897541 | 0.74 | P2RX3 (0.40) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2236505-A1 | Acylated aminopyridines and pyridazines as insecticides | Bayer CropScience AG (DE) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | AAAS, DDT, QDPR | L3MBTL1 1263/4885SMN1; SMN2 2519/4885ALDH1A1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.